The term "palliative care" often carries a negative connotation of giving up, causing patient resistance. Framing it as "supportive care" better emphasizes its role in managing symptoms to help patients tolerate cancer treatment longer and improve outcomes.
Historically considered "heresy," re-biopsy in pancreatic cancer is now an everyday practice. Initial samples often yield insufficient tissue for comprehensive genomic analysis, making subsequent biopsies of metastatic sites necessary to guide precision treatment.
Over 90% of patients on the new RAS inhibitor diraxin rasib develop a skin rash. The standard protocol involves prophylactic antibiotics like doxycycline, started *before* the first drug dose and continued for at least eight weeks, to mitigate this toxicity.
Clinicians are observing an alarming increase in pancreatic cancer diagnoses in younger individuals, often under 40 and sometimes even under 30. This shift mirrors trends in other GI cancers and points to unknown environmental or lifestyle factors.
The standard of care for pancreatic cancer includes ordering both germline (inherited) and somatic (tumor-specific) genetic tests at the initial patient visit. This "point-of-care" approach is crucial for identifying targetable mutations early on.
Clinicians emphasize that maintaining treatment continuity with a reduced, tolerable chemotherapy dose is superior to discontinuing therapy due to side effects. This approach helps patients stay on treatment longer, potentially improving overall survival.
A seminal study on metastatic lung cancer showed early palliative care integration led to better quality of life and longer median survival (11.6 vs 8.9 months), despite less aggressive end-of-life therapy, a counterintuitive but powerful finding.
Oncologists observe that newly diagnosed pancreatic cancer patients now frequently ask about clinical trials. This indicates a significant shift in patient education and empowerment, with individuals actively seeking the most novel treatments available from day one.
The pan-RAS inhibitor RMC-6236 (diraxin rasib) demonstrated a "stunning" hazard ratio of 0.4 in a Phase 3 trial for second-line metastatic pancreatic cancer, doubling median overall survival from 6.7 to 13 months compared to standard chemotherapy.
The FDA-approved Optune device, which uses tumor-treating fields, significantly improved median overall survival and pain-free survival for patients with locally advanced, unresectable pancreatic cancer when added to chemotherapy, offering a new non-invasive treatment option.
Oncologists co-order tissue and liquid biopsies for new pancreatic cancer patients. This is crucial because tissue samples are insufficient for genomic testing in roughly 20% of cases, making the liquid biopsy an essential backup for treatment planning.